Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186638 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
A Phase 2 study of Cognitive Impairment and Malignant Neoplasm, sponsored by University of Rochester NCORP Research Base.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT03186638: Completed Phase 2 study of Cognitive Impairment and Malignant Neoplasm, sponsored by University of Rochester NCORP Research Base.
NCT03186638 is a Phase 2 study of Cognitive Impairment and Malignant Neoplasm that has completed, run by University of Rochester NCORP Research Base. The registered enrollment target is 87 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03186638, a Phase 2 study of Cognitive Impairment and Malignant Neoplasm, has completed, sponsored by University of Rochester NCORP Research Base.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Primary Outcome
Will be assessed by the Functional Assessment of Cancer Therapy-Cognitive Function. Means, standard deviations, and 95% confidence intervals will be determined in order to estimate preliminary population variances and effect sizes. These statistical measures will be calculated by group for the Pre(Baseline) and Post(6 Weeks) measures of the Functional Assessment of Cancer Therapy-Cognitive Function scores as well as the change (post-pre) in the scores using the subjects that completed the study
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Ibuprofen
Study Locations (20)
Delaware
- Beebe Medical Center - Lewes
- Delaware Clinical and Laboratory Physicians PA - Newark
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Regional Hematology and Oncology PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Beebe Health Campus - Rehoboth Beach
- Nanticoke Memorial Hospital - Seaford
- Christiana Care Health System-Wilmington Hospital - Wilmington
Idaho
- Saint Luke's Mountain States Tumor Institute - Boise
- Saint Luke's Mountain States Tumor Institute - Fruitland - Fruitland
- Saint Luke's Mountain States Tumor Institute - Meridian - Meridian
- Saint Luke's Mountain States Tumor Institute - Nampa - Nampa
- Saint Luke's Mountain States Tumor Institute-Twin Falls - Twin Falls
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Memorial Hospital of Carbondale - Carbondale
- SIH Cancer Institute - Carterville
- Illinois CancerCare-Carthage - Carthage
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2017-05-26 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 2 |
What the finished NCT03186638 record still lists
NCT03186638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03186638 names 20 study sites across 4 states, led by Delaware, Idaho, Illinois.
Frequently Asked Questions
What is clinical trial NCT03186638 about?
NCT03186638 is a clinical study titled "Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer". This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
What is the current status of trial NCT03186638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2017-05-26. Estimated completion is 2022-06-01.
What conditions does trial NCT03186638 study?
This clinical trial studies the following conditions: Cognitive Impairment, Malignant Neoplasm.
What interventions are being tested in trial NCT03186638?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Ibuprofen (DRUG).
Who is sponsoring clinical trial NCT03186638?
This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03186638 being conducted?
This trial has 20 study locations across California, Delaware, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03186638's enrollment target sits among peer trials
87 51st of 105 higher than 55 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Cognitive Remediation Intervention to Prepare for Transition of Care
RECRUITING · Phase 2
-
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
COMPLETED · Phase 2
-
Gulf War Illness Inflammation Reduction Trial
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI